News

We're thrilled to share the latest developments from our company.

Suche

Notice to Annual General Meeting in ODI Pharma AB (publ)

The shareholders of ODI Pharma AB (publ), 559223–1392, are hereby invited to attend the Annual General Meeting on Monday, 30th of...

ODI Pharma

27. Nov. 20245 Min. Lesezeit

Kallelse till årsstämma i ODI Pharma AB (publ)

Aktieägarna i ODI Pharma AB (publ), 559223–1392, kallas härmed till årsstämma måndagen den 30 december 2024 kl. 10:00 i bolagets lokaler...

ODI Pharma

27. Nov. 20244 Min. Lesezeit

The subscription period in ODI Pharma AB’s preferential rights issue commences today

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA,...

ODI Pharma

26. Nov. 20247 Min. Lesezeit

ODI Pharma AB publishes memorandum prior to preferential rights issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA,...

ODI Pharma

25. Nov. 20244 Min. Lesezeit

Publication of interim report Q1 2024/2025

ODI Pharma AB (“ODI” or the “Company”) hereby publishes its interim report for the period July 2024 – September 2024. The report is...

ODI Pharma

22. Nov. 20243 Min. Lesezeit

ODI Pharma moves the AGM and postpones the publication of Annual Report 2023/2024

ODI Pharma AB (“ODI” or the “Company”) hereby hereby announces that the Company, due to administrative reasons, chooses to move the...

ODI Pharma

22. Nov. 20242 Min. Lesezeit

Report from the Extraordinary General Meeting on 19 November in ODI Pharma AB (publ)

Today, 19 November 2024, an Extraordinary General Meeting was held in ODI Pharma AB (publ), reg. no. 559223-1392. Below is a summary of...

ODI Pharma

19. Nov. 20243 Min. Lesezeit

Kommuniké från extra bolagsstämma den 19 november i ODI Pharma AB (publ)

Idag, den 19 november 2024, hölls extra bolagsstämma i ODI Pharma AB (publ), org. nr. 559223-1392. Nedan följer en sammanfattning av de...

ODI Pharma

19. Nov. 20242 Min. Lesezeit

Updated Notice of Annual General Meeting in ODI Pharma AB (publ)

The shareholders of ODI Pharma AB (publ), 559223-1392, are hereby summoned to the Annual General Meeting on Friday, December 13, 2024, at...

ODI Pharma

13. Nov. 20246 Min. Lesezeit

Uppdaterad kallelse till årsstämma i ODI Pharma AB (publ)

Aktieägarna i ODI Pharma AB (publ), 559223-1392, kallas härmed till årsstämma fredagen den 13 december 2024 kl. 10:00 i bolagets lokaler...

ODI Pharma

13. Nov. 20245 Min. Lesezeit

ODI Pharma appoints new CEO

The board of ODI Pharma AB (“ODI” or the “Company”) has today appointed Jan-Mark Edewaard as the new CEO of ODI as of January 1, 2025....

ODI Pharma

12. Nov. 20243 Min. Lesezeit

Kallelse till årsstämma i ODI Pharma AB (publ)

Aktieägarna i ODI Pharma AB (publ), 559223–1392, kallas härmed till årsstämma fredagen den 13 december 2024 kl. 10:00 i bolagets lokaler...

ODI Pharma

12. Nov. 20244 Min. Lesezeit

Notice to Annual General Meeting in ODI Pharma AB (publ)

The shareholders of ODI Pharma AB (publ), 559223–1392, are hereby invited to attend the Annual General Meeting on Friday, 13th of...

ODI Pharma

12. Nov. 20245 Min. Lesezeit

Kallelse till extra bolagsstämma i ODI Pharma AB (publ)

Aktieägarna i ODI Pharma AB (publ), 559223-1392 , kallas härmed till extra bolagsstämma tisdagen den 19 november 2024 kl. 14.30 i...

ODI Pharma

30. Okt. 20245 Min. Lesezeit

Notice of Extraordinary General Meeting in ODI Pharma AB (publ)

The shareholders of ODI Pharma AB (publ), 559223-1392 , are hereby invited to an Extraordinary General Meeting to be held on Tuesday 19...

ODI Pharma

30. Okt. 20246 Min. Lesezeit

Proposal for change in the Board of Directors of ODI Pharma AB

Malcolm Allan is proposed to be elected as a new member of the Board of Directors of ODI Pharma AB at the Extraordinary General Meeting...

ODI Pharma

30. Okt. 20242 Min. Lesezeit

ODI Pharma AB decides on a preferential issue of shares and to bring forward publication of the Q1-report

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA,...

ODI Pharma

30. Okt. 20248 Min. Lesezeit

Publication of year-end report for the fiscal year 2023/2024

ODI Pharma AB (“ODI” or the “Company”) hereby publishes its year-end report for the period July 2023 – June 2024. The report is available...

ODI Pharma

29. Aug. 20244 Min. Lesezeit

ODI Pharma AB announces strategic market entry with initial shipment to Switzerland

ODI Pharma AB (“ODI” or the “Company”) is pleased to announce the first delivery of cannabis products to the leading medical cannabis...

ODI Pharma

25. Juni 20242 Min. Lesezeit

ODI Pharma AB: Publication of interim report Q3 2023/2024

ODI Pharma AB (“ODI” or the “Company”) hereby publishes its interim report for the period July 2023 - March 2024. The report is available...

ODI Pharma

30. Mai 20244 Min. Lesezeit